What is the next big thing for your company's portfolio?

To help pharmaceutical companies answer this question, Kaiser Associates conducted a comprehensive analysis of nearly every pharma R&D program in the world and compiled the findings into the fourth annual Hot Indications List.

The 2018 edition includes:
  • Analysis of the Top Movers from last year's list
  • An updated Top 100 List of indications
  • Orphan Hot Indications analysis
  • Insights on recent acquisitions, drug approvals, and pipeline activity

Complete the form to download your free whitepaper now!